Gilead Sciences, Inc.
Close on Nov 2, 2026Market cap $211.20BP/E –Yield 1.86%
Gilead Sciences Gilead R&D expense recorded under Arcus Biosciences by Year
Gilead R&D expense recorded under Arcus Biosciences collaboration ($M) ($M)
Gilead Sciences Gilead R&D expense recorded under Arcus Biosciences: $218M in FY2025, down 10.3% from a year earlier.
Where the FY2025 figure comes from
Source: Form 10-K (filed 2026-02-24) ↗
Reported in Form 10-K Note 7 Collaborations and Other Arrangements.
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Gilead R&D expense recorded under Arcus Biosciences collaboration ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 218 | -10.3% | Form 10-K (filed 2026-02-24) ↗ |
| FY2024 | Dec 31, 2024 | 243 | +28.6% | Form 10-K (filed 2026-02-24) ↗ |
| FY2023 | Dec 31, 2023 | 189 | +1.1% | Form 10-K (filed 2026-02-24) ↗ |
| FY2022 | Dec 31, 2022 | 187 | -70.1% | Form 10-K (filed 2025-02-28) ↗ |
| FY2021 | Dec 31, 2021 | 625 | – | Form 10-K (filed 2022-02-23) ↗ |
Cite this data
StockData. (2026). Gilead Sciences Gilead R&D expense recorded under Arcus Biosciences ($M), annual FY2021–FY2025 [Data set]. Compiled from Gilead Sciences SEC filings and investor materials. https://stockdatahq.com/stocks/gild/kpis/rd-arcus-collab
See every metric in the Gilead Sciences KPI table. Data updated Oct 29, 2026.